Anti-Human/Mouse integrin β7 (Clone FIB21) – Purified in vivo GOLD™ Functional Grade
Pricing & Details
≥ 5.0 mg/ml
< 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Anti-Human/Mouse integrin β7 activity is directed against human and mouse β7 integrin.
Integrin β7 heterodimer α4/β7 is expressed on peripheral lymphocytes, thymocytes and bone marrow progenitors. Integrin β7 heterodimer αE/β7 is expressed on intestinal IEL, dendritic epidermal T cells, T regulatory cells, CD8+ T cells in lymph nodes and lamina propria.
Integrins are a large family of heterodimeric transmembrane molecules that mediate adhesion, migration, cell survival, and cell differentiation. β7 can pair with CD49d to form the heterodimeric integrin receptor α4β7 or with CD103 to form αEβ7. α4β7 integrin is a lymphocyte receptor for the mucosal vascular addressin MADCAM-11. αEβ7 is an α-I domain-containing integrin that is highly expressed by a variety of leukocyte populations at mucosal sites including dendritic cells, intraepithelial T cells, mast cells, and T regulatory cells.
FIB21 was generated by immunizing Wister rats with TK1 murine T cell lymphoma cells2. Spleen cells were then fused with Sp2/0-Ag14 myeloma cells to create a hybridoma line. FIB21 is known to block adhesion to MADCAM-1 and E-cadherin as well as α4β7 integrin binding to VCAM-1 and fibronectin. FIB21 maps to amino acid resides 176-250, which lie within the region of β7 that specifies MADCAM-1 binding3.
CD49d/ß7: VCAM-1 (CD106), MAdCAM-1 and fibronectin; CD103/ß7: E-cadherin
Lymphocyte adhesion, hematopoietic progenitor cells migration
References & Citations
1. Berlin C, Berg EL, Briskin MJ, et al. Cell. 74(1):185-195. 1993.
2. Andrew DP, Berlin C, Honda S, et al. J Immunol. 153(9):3847-3861. 1994.
3. Tidswell M, Pachynski R, Wu SW, et al. J Immunol. 159(3):1497-1505. 1997.
4. Meerschaert J, Vrtis RF, Shikama Y, et al. J Immunol. 163(11):6217-6227. 1999.
5. Higgins JM, Cernadas M, Tan K, et al. J Biol Chem. 275(33):25652-25664. 2000.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.